ClinicalTrials.gg
Active, not recruitingNCT03199469ASPIROUpdated Nov 13, 2026Results posted

A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)

A Phase 2/3 interventional study of Resamirigene bilparvovec in X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies. Active, not recruiting at 6 sites in 4 countries. Open to male participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 13, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
Up to 5 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Myopathies, Structural, Congenital with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Myopathies, Structural, Congenital · United States.

Started
2017
the only one that year
Phase 2/3
Only one
of the 13
Registered
8th of 13
by date
Lead sponsor
5 of 13
Astellas Gene Therapies

Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, this one is the only one that started in 2017, is the only one in phase 2/3, and was the 8th registered.

Myopathies, Structural, Congenital

24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.

Browse Myopathies, Structural, Congenital studies →

Open to participants now

4 of the 13 studies in Myopathies, Structural, Congenital with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Myopathies, Structural, Congenital studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: Up to 5 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myopathies, Structural, Congenital with a site in United States, or all of them as a file.
02

Study summary

X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no therapies for this serious condition.

The protein myotubularin is needed for muscle development and movement. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene causes low levels of myotubularin to be made, so the muscles do not work properly. XLMTM may also affect the liver, and in some cases, this can be dangerous and threaten the patient´s life.

Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. AT132 is a gene therapy that gets a healthy MTM1 gene into the body to help improve muscle development and function in young children with the disease. AT132 does not treat liver disease, and because of the way the treatment works, it may make liver problems worse.

AT132 was the gene therapy treatment given to children who participated in this study and is not available to the public. In this study, AT132 was given to children for the first time. Due to the occurrence of severe complications and fatalities associated with administration of AT132, the study has been stopped and no further participants will be enrolled.

The main aim of the study is to check how long young children need machines to support breathing (ventilation support) after AT132.

Due to the occurrence of severe complications and fatalities associated with administration of AT132, the study has been stopped and no further participants will be enrolled. This study included children with XLMTM under 5 years old who had breathing problems caused by XLMTM. They couldn't take part if they were born prematurely, recently had surgery, had liver disease or other condition or disease the study doctor thought was medically important. The study did enroll participants with medically significant liver disease.

This is an open-label study. This means that young children and their caregivers, and clinic staff know that young children received AT132. This study was designed with 2 parts and is now in a long-term follow-up phase to collect information on the safety and improvements in muscle function in the children who received AT132.

In Part 1, small groups of young children were given different doses of AT132, with one group receiving a lower dose and one group receiving a higher dose of AT132. The purpose of giving the two doses was to determine which dose was best for treating the muscle disease. After receiving AT132, a medical panel of experts reviewed each child for safety and for how their muscles responded. AT132 did not demonstrate appropriate safety at either dose. Administration of AT132 was stopped. Children who received AT132 are being monitored for 10 years for safety and to understand how their muscles function over time.

Read the detailed description

This study evaluated safety and efficacy of gene transfer in X-Linked Myotubular Myopathy. Participants received a single dose of resamirigene bilparvovec delivered intravenously.

ASPIRO was being conducted in two parts. Part 1 was a dose escalation phase that was evaluating the preliminary safety and efficacy of Resamirigene bilparvovec at doses of 1.3x10\^14 vg/kg and 3.5x10\^14 vg/kg. Part 2 of ASPIRO was a pivotal expansion cohort designed to confirm the safety and efficacy of resamirigene bilparvovec at a dose of 3.5x10\^14 vg/kg. The pivotal expansion cohort enrolled eight participants, consisting of four age-matched pairs (within +/- 6 months of age). One participant from each pair was randomized to receive a single dose of resamirigene bilparvovec at 3.5x10\^14 vg/kg, and the other served as a delayed treatment control. Eligible delayed treatment control participants administered resamirigene bilparvovec after that individual participant completed the Week 24 visit as a delayed treatment control.

The primary efficacy endpoint measures assessed at Week 24. Participants were followed for a total of 10 years after administration of resamirigene bilparvovec. Only Part 1 of the study was reported.

This study utilized an independent Data Monitoring Committee (DMC) that monitored participant safety and provided recommendations to Astellas regarding dose escalation, dose expansion, and safety matters.

03

Conditions studied

  • X-Linked Myotubular Myopathy

Keywords

  • AAV8-Delivered Gene Therapy
  • XLMTM
  • Adeno Associated Virus
04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene as assessed by a Sponsor-approved testing facility.
  • Subject is male.
  • Subject is aged less than 5 years old at dosing
  • Subject requires mechanical ventilatory support:

Part 1: Subject requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full time mechanical ventilation, to noninvasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours).

Part 2: Subject requires invasive mechanical ventilatory support ranging from 20 - 24 hours per day at screening (confirmed by daytime polysomnographic study).

  • Subject requiring invasive mechanical ventilator support is fitted with or willing to be fitted with a cuffed tracheostomy tube for some respiratory assessments.
  • Subject has ventilator maximum positive end-expiratory pressure (PEEP) \<8 cm H2O at screening.
  • UNIQUE to France: Subject's weight is ≥ 4.8 kg.

Exclusion criteria

Exclusion Criteria:

  • Subject is participating in an interventional study designed to treat XLMTM.
  • Subject born \<35 weeks gestation who is still not term as per corrected age.
  • Subject tests positive for AAV8 neutralizing antibody with titers above protocol specified threshold.
  • Subject had recent surgery (\<3 months before Day 1) or has planned surgery that may confound data collection during the first 48 weeks of the study.
  • Subject has a condition other than XLMTM in the opinion of the investigator.
  • Subject has a clinically significant underlying liver disease.
  • Subject is currently experiencing a clinically important respiratory infection or other active infection.
  • Subject has received pyridostigmine or any medication to treat XLMTM within 3 months before Day 1.
  • Other than as required per protocol, subject has received immune-modulating agents within 3 months before Day 1 (use of inhaled to manage chronic respiratory conditions is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 4 weeks before dosing.
  • Subject has a to prednisolone.
  • Subject has a contraindication to study drug or ingredients.
  • Subject has previous scoliosis repair surgery/procedure, or planned/expected scoliosis repair surgery/procedure in the 12 months following Day 1 (Part 2 including any subjects enrolled under protocol v8 and beyond).
  • Subject has contractures, scoliosis, or other medical condition that would limit the potential to achieve unassisted sitting, in the opinion of the investigator (Part 2 including any subjects enrolled under protocol V8 and beyond).
  • Subject is able to sit without assistance for at least 30 seconds at screening, in the opinion of the investigator (Part 2 including any subjects enrolled under protocol V8 and beyond).
  • Subject has a clinically important condition, including v4.03 Grade ≥ 2 anemia (\< 10 g/dL ).
  • Subject has a contraindication to ursodiol (ursodeoxycholic acid).
  • UNIQUE to France: Subject has a prior diagnosis or history of cardiac arrhythmias, myocarditis, or any other cardiac disease.
  • UNIQUE to France: Subject has a contraindication to general anesthesia and to muscle procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    1.3 × 10^14 vg/kg (Low dose)

    Participants received 1.3 x 10\^14 viral genomes per kilogram (vg/kg) of body weight resamirigene bilparvovec as a single dose intravenously on Day 1. A sentinel dose was given to first participant and if there were no safety concerns, subsequent participants received either resamirigene bilparvovec at the same dose or control with delayed treatment after at least 4 weeks of post-dose data from the sentinel participant.

    Genetic: Resamirigene bilparvovec

  • Experimental
    3.5 × 10^14 vg/kg (High dose)

    Participants received 3.5 × 10\^14 vg/kg of body weight resamirigene bilparvovec as a single dose intravenously on Day 1. A sentinel dose was given to first participant and if there were no safety concerns, subsequent participants received either resamirigene bilparvovec at the same dose or control with delayed treatment after at least 4 weeks of post-dose data from the sentinel participant.

    Genetic: Resamirigene bilparvovec

Interventions

  • GeneticResamirigene bilparvovec

    Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.

    Also known as: AT132

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hours of Ventilation Support at Week 24

    The hours of ventilation support were based on diary data from participants for whom diary data was collected at baseline and by assessment of time off ventilator questionnaire for all other participants. Weekly scores were the average of ventilation hours needed for at least 5 out of the 7 days leading up to and including the analysis visit day (e.g., Day 168 for Week 24). For cases where the diary or the ventilator assessment indicated the ventilator type = "None", then zero was imputed for the number of hours on ventilator.

    Time frame: Baseline, week 24

Secondary outcomes

  1. Percentage of Participants Achieving Functionally Independent Sitting for At Least 30 Seconds by Week 24

    Independence to sit is defined as a participant who sits for at least 30 seconds without assistance from another person or object. Data was determined from the motor milestone electronic case report form (eCRF) or the Bayley Scales of Infant and Toddler Development (BSID) subtest performance criteria number 26, used to determine whether the participant achieves (Yes) or doesn't achieve (No) the milestone. If data was not available then they would be included as "missing".

    Time frame: Week 24

  2. Time to Reduction in Required Ventilator Support to ≤ 16 Hours a Day From Dosing to Week 24

    The reduced ventilator time was obtained directly from the daily diary or assessment of the time off ventilator questionnaire. The first instance of time reduction reported as ≤ 16 hours per day was considered as an event. Kaplan- Meier estimate was used for analysis.

    Time frame: Baseline up to week 24

  3. Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Total Score at Week 24

    The CHOP INTEND is an assessment scale that was originally designed to quantify motor abilities in infants aged 1.4 to 37.9 months, with spinal muscular atrophy type I (SMA-I) and has been validated for X-linked myotubular myopathy (XLMTM). The scale contains 16 questions, each of which is scored on a scale of 0 to 4, with 0 being no response/ability to perform the movement and 4 highest abilities to perform the task, per CHOP INTEND item instructions. The score used for analysis is the total sum of all 16 questions, which will range from 0 to 64. Higher score indicates better neuromuscular function. If an item is missing or scored as "Could Not Test (CNT)" then 0 will be imputed for the item score.

    Time frame: Baseline, week 24

  4. Change From Baseline in Maximal Inspiratory Pressure (MIP) at Week 24

    MIP is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible.

    Time frame: Baseline, week 24

  5. Change From Baseline in Quantitative Analysis of Myotubularin Expression in the Muscle Biopsy at Week 24

    Myotubularin is a protein, a highly conserved, dual-specific lipid phosphatase that is involved in the development, maturation, and maintenance of skeletal muscle cells. Myotubularin is encoded by an MTM1 gene. The concentration of the sample was normalized such that the equivalent amount of protein was tested per sample.

    Time frame: Baseline, week 24

  6. Change From Baseline in Quality of Life Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Total Score at Week 24

    ACEND was developed to measure impact on lives of parents/legally authorized representatives /caregivers caring for children with severe neuromuscular disorders. ACEND has 41 items which reflected 2 domains (physical impact \[feeding/grooming/dressing {6 items}, sitting/play {5 items}, transfers {5 items} and mobility {7 items}\] and general caregiver impact \[time {4 items}, emotion {9 items}, and finance {5 items}\]). Score for each item was based on 6- or 5-point ordinal scale, and scores for each domain and subdomain were scored on 0 - 100 scale. Higher scores reflected caregivers experiencing less intense care-giving impact. Raw scores for each subdomain was created by computing algebraic mean of items for those respondents who completed one item or more; setting missing for those items with no responses. Then, arithmetic mean of responded items was standardized to 0 to 100 score and transformed scores were from 0 to 100 for each subdomain. Higher score indicated a better outcome.

    Time frame: Baseline, week 24

  7. Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Assessment Total Score at Week 24

    PedsQL is a tool designed to measure health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. PedsQL measures the core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. This questionnaire has different modules that are administered depending on the age and condition of the child. Each item of the questionnaire is measured on a 5-point likert scale from - 0 (Never) to 4 (Almost always). The module is composed of 25 items comprising 3 dimensions: About My Neuromuscular Disease (17 items), Communication (3 items), About Our Family Resources (5 items). Items are reversed scored and linearly transformed to a total score of 0-100 scale. Higher scales/scores indicate lower problems.

    Time frame: Baseline, week 24

  8. Mean Percent of Age-appropriate Clinically Relevant Gross Motor Function Milestones Attained Through Week 24

    Motor Developmental Milestones included: head control (holds head erect for at least 15 seconds without support), rolls from back to sides (turns from back to both sides), sits without support (sits alone without support for at least 10 seconds), stands with assistance (supports own weight for at least 2 seconds), crawls (makes forward progress of at least 5 feet by crawling on hands and knees), pulls to stand (raises self to standing position using chair or other convenient object for support), walks with assistance (child walks by making coordinated, alternating stepping movements. May hold on with 1 or 2 hands for support), stands alone (stands alone for at least 3 seconds after you release hands), walks alone (takes at least 3 steps without support, even if gait is stiff-legged and wobbly). Mean percentage of gross motor function milestones attained was reported.

    Time frame: Baseline, weeks 4, 12, 16 and 24

  9. Percentage of Participants Achieving Full Ventilator Independence at Week 24

    "Full ventilator independence" is defined as: the date of removal from ventilator field on the "Assessment of Ventilator Parameters" eCRF is not blank or "Is subject on a ventilator" = "No" on the same eCRF.

    Time frame: Week 24

  10. Duration of Overall Survival

    Survival status was assessed at each visit until the participant withdraws consent or completes the study. If the participant missed a visit or withdraws for a reason other than withdrawal of consent or death, the site contacted the parent(s)/legally authorized representatives to ascertain if the participant was alive. For participants who withdrew from the study, the participant was contacted every 6 months for 5 years after administration and to assess for survival. Kaplan- Meier estimate was used for analysis.

    Time frame: Baseline up to 5 years

  11. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant administered a study drug not necessarily having a causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. A TEAE is any AEs, regardless of relationship to study drug, that begins or worsens on or after baseline (dosing) visit date.

    Time frame: From first dose to 5 years

07

Results

Posted Aug 20, 2024

Participant flow

Participants diagnosed with X-linked myotubular myopathy (XLMTM) resulting from a genetically confirmed mutation in the myotubular myopathy (MTM) 1 gene as assessed by a Sponsor-approved testing facility were enrolled in this study.

Participant flow — Overall Study
Milestone1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Started720
Delayed treatment control (dtc) group16
Immediate treatment group614
Completed00
Not completed720
Withdrew: Randomized, not treated03
Withdrew: Withdrawal by subject10
Withdrew: Death13
Withdrew: Ongoing514

Outcome measures

PrimaryChange From Baseline in Hours of Ventilation Support at Week 24

The hours of ventilation support were based on diary data from participants for whom diary data was collected at baseline and by assessment of time off ventilator questionnaire for all other participants. Weekly scores were the average of ventilation hours needed for at least 5 out of the 7 days leading up to and including the analysis visit day (e.g., Day 168 for Week 24). For cases where the diary or the ventilator assessment indicated the ventilator type = "None", then zero was imputed for the number of hours on ventilator.

Time frame:
Baseline, week 24
Reported as:
Mean · hours
Change From Baseline in Hours of Ventilation Support at Week 24
hours1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Change From Baseline in Hours of Ventilation Support at Week 24-8.92 ± 9.31-5.84 ± 5.45
SecondaryPercentage of Participants Achieving Functionally Independent Sitting for At Least 30 Seconds by Week 24

Independence to sit is defined as a participant who sits for at least 30 seconds without assistance from another person or object. Data was determined from the motor milestone electronic case report form (eCRF) or the Bayley Scales of Infant and Toddler Development (BSID) subtest performance criteria number 26, used to determine whether the participant achieves (Yes) or doesn't achieve (No) the milestone. If data was not available then they would be included as "missing".

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Functionally Independent Sitting for At Least 30 Seconds by Week 24
Percentage of participants1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Achieved83.361.5
Not Achieved16.738.5
SecondaryTime to Reduction in Required Ventilator Support to ≤ 16 Hours a Day From Dosing to Week 24

The reduced ventilator time was obtained directly from the daily diary or assessment of the time off ventilator questionnaire. The first instance of time reduction reported as ≤ 16 hours per day was considered as an event. Kaplan- Meier estimate was used for analysis.

Time frame:
Baseline up to week 24
Reported as:
Median · Weeks
Time to Reduction in Required Ventilator Support to ≤ 16 Hours a Day From Dosing to Week 24
Weeks1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Time to Reduction in Required Ventilator Support to ≤ 16 Hours a Day From Dosing to Week 2412.1 (4.1 to 16.1)NA (17.1 to NA)
SecondaryChange From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Total Score at Week 24

The CHOP INTEND is an assessment scale that was originally designed to quantify motor abilities in infants aged 1.4 to 37.9 months, with spinal muscular atrophy type I (SMA-I) and has been validated for X-linked myotubular myopathy (XLMTM). The scale contains 16 questions, each of which is scored on a scale of 0 to 4, with 0 being no response/ability to perform the movement and 4 highest abilities to perform the task, per CHOP INTEND item instructions. The score used for analysis is the total sum of all 16 questions, which will range from 0 to 64. Higher score indicates better neuromuscular function. If an item is missing or scored as "Could Not Test (CNT)" then 0 will be imputed for the item score.

Time frame:
Baseline, week 24
Reported as:
Mean · Score on scale
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Total Score at Week 24
Score on scale1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Total Score at Week 2411.86 ± 15.1213.25 ± 13.35
SecondaryChange From Baseline in Maximal Inspiratory Pressure (MIP) at Week 24

MIP is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible.

Time frame:
Baseline, week 24
Reported as:
Mean · centimeter of water (cmH2O)
Change From Baseline in Maximal Inspiratory Pressure (MIP) at Week 24
centimeter of water (cmH2O)1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Change From Baseline in Maximal Inspiratory Pressure (MIP) at Week 2441.07 ± 35.0326.72 ± 28.35
SecondaryChange From Baseline in Quantitative Analysis of Myotubularin Expression in the Muscle Biopsy at Week 24

Myotubularin is a protein, a highly conserved, dual-specific lipid phosphatase that is involved in the development, maturation, and maintenance of skeletal muscle cells. Myotubularin is encoded by an MTM1 gene. The concentration of the sample was normalized such that the equivalent amount of protein was tested per sample.

Time frame:
Baseline, week 24
Reported as:
Mean · picograms (pg)/15 microgram(µg) protein
Change From Baseline in Quantitative Analysis of Myotubularin Expression in the Muscle Biopsy at Week 24
picograms (pg)/15 microgram(µg) protein1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Change From Baseline in Quantitative Analysis of Myotubularin Expression in the Muscle Biopsy at Week 24923.69 ± 816.092848.40 ± 2903.83
SecondaryChange From Baseline in Quality of Life Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Total Score at Week 24

ACEND was developed to measure impact on lives of parents/legally authorized representatives /caregivers caring for children with severe neuromuscular disorders. ACEND has 41 items which reflected 2 domains (physical impact \[feeding/grooming/dressing {6 items}, sitting/play {5 items}, transfers {5 items} and mobility {7 items}\] and general caregiver impact \[time {4 items}, emotion {9 items}, and finance {5 items}\]). Score for each item was based on 6- or 5-point ordinal scale, and scores for each domain and subdomain were scored on 0 - 100 scale. Higher scores reflected caregivers experiencing less intense care-giving impact. Raw scores for each subdomain was created by computing algebraic mean of items for those respondents who completed one item or more; setting missing for those items with no responses. Then, arithmetic mean of responded items was standardized to 0 to 100 score and transformed scores were from 0 to 100 for each subdomain. Higher score indicated a better outcome.

Time frame:
Baseline, week 24
Reported as:
Mean · Score on scale
Change From Baseline in Quality of Life Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Total Score at Week 24
Score on scale1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Change From Baseline in Quality of Life Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Total Score at Week 2420.12 ± 18.8113.82 ± 12.33
SecondaryChange From Baseline in Pediatric Quality of Life Inventory (PedsQL) Assessment Total Score at Week 24

PedsQL is a tool designed to measure health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. PedsQL measures the core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. This questionnaire has different modules that are administered depending on the age and condition of the child. Each item of the questionnaire is measured on a 5-point likert scale from - 0 (Never) to 4 (Almost always). The module is composed of 25 items comprising 3 dimensions: About My Neuromuscular Disease (17 items), Communication (3 items), About Our Family Resources (5 items). Items are reversed scored and linearly transformed to a total score of 0-100 scale. Higher scales/scores indicate lower problems.

Time frame:
Baseline, week 24
Reported as:
Mean · Score on scale
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Assessment Total Score at Week 24
Score on scale1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Assessment Total Score at Week 249.39 ± 15.5112.06 ± 19.23
SecondaryMean Percent of Age-appropriate Clinically Relevant Gross Motor Function Milestones Attained Through Week 24

Motor Developmental Milestones included: head control (holds head erect for at least 15 seconds without support), rolls from back to sides (turns from back to both sides), sits without support (sits alone without support for at least 10 seconds), stands with assistance (supports own weight for at least 2 seconds), crawls (makes forward progress of at least 5 feet by crawling on hands and knees), pulls to stand (raises self to standing position using chair or other convenient object for support), walks with assistance (child walks by making coordinated, alternating stepping movements. May hold on with 1 or 2 hands for support), stands alone (stands alone for at least 3 seconds after you release hands), walks alone (takes at least 3 steps without support, even if gait is stiff-legged and wobbly). Mean percentage of gross motor function milestones attained was reported.

Time frame:
Baseline, weeks 4, 12, 16 and 24
Reported as:
Mean · Percentage of gross motor function
Mean Percent of Age-appropriate Clinically Relevant Gross Motor Function Milestones Attained Through Week 24
Percentage of gross motor function1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Baseline0.012.50 ± 15.81
Week 430.00 ± 28.2823.33 ± 19.66
Week 120.026.85 ± 15.06
Week 160.025.25 ± 16.26
Week 240.026.67 ± 19.36
SecondaryPercentage of Participants Achieving Full Ventilator Independence at Week 24

"Full ventilator independence" is defined as: the date of removal from ventilator field on the "Assessment of Ventilator Parameters" eCRF is not blank or "Is subject on a ventilator" = "No" on the same eCRF.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Full Ventilator Independence at Week 24
Percentage of participants1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Achieved28.60
Not Achieved71.4100
SecondaryDuration of Overall Survival

Survival status was assessed at each visit until the participant withdraws consent or completes the study. If the participant missed a visit or withdraws for a reason other than withdrawal of consent or death, the site contacted the parent(s)/legally authorized representatives to ascertain if the participant was alive. For participants who withdrew from the study, the participant was contacted every 6 months for 5 years after administration and to assess for survival. Kaplan- Meier estimate was used for analysis.

Time frame:
Baseline up to 5 years
Reported as:
Median · Months
Duration of Overall Survival
Months1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Duration of Overall SurvivalNA (2.10 to NA)NA (NA to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant administered a study drug not necessarily having a causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. A TEAE is any AEs, regardless of relationship to study drug, that begins or worsens on or after baseline (dosing) visit date.

Time frame:
From first dose to 5 years
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Participants1.3 × 10^14 vg/kg (Low Dose)3.5 × 10^14 vg/kg (High Dose)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)717

Adverse events

Collected over From first dose to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.3 x 10^14 vg/kg (Low Dose)1/7 (14.3%)5/7 (71.4%)7/7 (100%)
3.5 x 10^14 vg/kg (High Dose)3/17 (17.6%)13/17 (76.5%)17/17 (100%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
Event1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)
AscitesGastrointestinal disorders0/73/17
Atrial tachycardiaCardiac disorders1/70/17
Cardiac arrestCardiac disorders1/70/17
MyocarditisCardiac disorders1/71/17
HyperbilirubinaemiaHepatobiliary disorders1/72/17
HypertransaminasaemiaHepatobiliary disorders1/71/17
Metapneumovirus infectionInfections and infestations1/70/17
Pneumonia parainfluenzae viralInfections and infestations1/70/17
Pneumonia pseudomonalInfections and infestations1/70/17
Pneumonia respiratory syncytial viralInfections and infestations1/70/17
Most frequent other events
Showing 10 of 294
Most frequent other events
Event1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)
PyrexiaGeneral disorders5/710/17
Blood creatine phosphokinase increasedInvestigations5/76/17
Otitis mediaInfections and infestations4/74/17
Viral upper respiratory tract infectionInfections and infestations4/75/17
ThrombocytopeniaBlood and lymphatic system disorders2/79/17
VomitingGastrointestinal disorders1/79/17
DiarrhoeaGastrointestinal disorders3/73/17
Upper respiratory tract infectionInfections and infestations3/77/17
C-reactive protein increasedInvestigations3/75/17
Transaminases increasedInvestigations3/73/17

Baseline characteristics

Included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(Months)1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)Total
Mean21.78 ± 15.4737.66 ± 24.5533.54 ± 23.37
Sex: Female, Male
Sex: Female, Male(Participants)1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)Total
Female000
Male72027
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)Total
Hispanic or Latino369
Not Hispanic or Latino41317
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American044
White71421
More than one race000
Unknown or Not Reported011
Ventilation Support
Ventilation Support(hours)1.3 x 10^14 vg/kg (Low Dose)3.5 x 10^14 vg/kg (High Dose)Total
Mean21 ± 4.6923.71 ± 0.5222.89 ± 2.8
08

Study locations

6 sites
  • UCLA Medical Center
    Los Angeles, California 90005, United States
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • National Institute of Neurological Disorders and Stroke/NIH Porter
    Bethesda, Maryland 208892, United States
  • Site CA15116
    Toronto, Ontario, Canada
  • Site FR33117
    Paris, France
  • Site DE49115
    München, Germany
09

References and documents

Publications

  • Shieh PB, Kuntz NL, Dowling JJ, Muller-Felber W, Bonnemann CG, Seferian AM, Servais L, Smith BK, Muntoni F, Blaschek A, Foley AR, Saade DN, Neuhaus S, Alfano LN, Beggs AH, Buj-Bello A, Childers MK, Duong T, Graham RJ, Jain M, Coats J, MacBean V, James ES, Lee J, Mavilio F, Miller W, Varfaj F, Murtagh M, Han C, Noursalehi M, Lawlor MW, Prasad S, Rico S. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023 Dec;22(12):1125-1139. doi: 10.1016/S1474-4422(23)00313-7. PubMed 37977713 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Sep 2021, 49 months.

Results were first posted in Aug 2024, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2017
First posted
Jun 27, 2017
StartActual
Aug 2, 2017
Primary completionActual
Sep 9, 2021
CompletionEst.
Mar 31, 2030
Results first posted
Aug 20, 2024
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (1 Canada, 1 France, 1 Germany)
  • Site CA15116 · Toronto, Canada
  • Site FR33117 · Paris, France
  • Site DE49115 · München, Germany
Show 3 removed
  • Hospital for Sick Children · Toronto, Canada
  • Hopital Armad Trousseau · Paris, France
  • Kinderklinik und Kinderpoliklinik im Dr. Von Haunerschen Kinderspital Klinikum der Universitat Munchen · München, Germany
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    3 sites added, 3 sites removed
    Show 3 added (1 Canada, 1 France, 1 Germany)
    • Site CA15116 · Toronto, Canada
    • Site FR33117 · Paris, France
    • Site DE49115 · München, Germany
    Show 3 removed
    • Hospital for Sick Children · Toronto, Canada
    • Hopital Armad Trousseau · Paris, France
    • Kinderklinik und Kinderpoliklinik im Dr. Von Haunerschen Kinderspital Klinikum der Universitat Munchen · München, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03199469
Responsible party
Sponsor
First posted
Jun 27, 2017
Start date
Aug 2, 2017
Primary completion
Sep 9, 2021
Completion
Mar 31, 2030 (estimated)
Results posted
Aug 20, 2024
Last update
Nov 13, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion